COMP <GO>
GH vs CNC // ENTERPRISE SCALE & MARKET CAP
Guardant Health Inc. (NASDAQ) VS. Centene Corporation (NYSE) • 15-METRIC TALLY: GH 6
— CNC 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CNC
LAST: $170.73 (-4.51%) • MKT CAP: $23.99B
market-cap
$23.99B
LAST: $66.53 (-2.80%) • MKT CAP: $33.89B
market-cap
$33.89B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. CNC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | CNC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 8.10% | +56.40 | GH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | -31.00% | +13.60 | GH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 12.72% | -13.66 | CNC | /fcf-yield <GO> |
| Operating Margin | -44.50% | -4.40% | -40.10 | CNC | /operating-margins <GO> |
| Net Profit Margin | -42.40% | -3.80% | -38.60 | CNC | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 20.00% | +12.90 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 2.52 | +2.92 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 53.2 | +1.70 | GH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.94 | -0.07 | CNC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 36.0x | -17.00 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $23.99B | $33.89B | -$9.89B | CNC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | CNC REV | GH GROSS % | CNC GROSS % | GH FCF | CNC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $174.58B | 64.5% | 8.1% | -$233.1M | $4.32B |
| FY 2024 | $739.0M | $145.50B | 60.8% | 11.7% | -$274.9M | -$490.0M |
| FY 2023 | $563.9M | $140.09B | — | — | -$350.4M | $1.75B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
CNC // BETA 0.94